Benefits and harms of extending the duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents: A meta-analysis

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Kwok, Chun Shing ^a   Bulluck, Heerajnarain ^b   Ryding, Alisdair D ^b   Loke, Yoon K ^a,b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL; PRASUGREL; RAPAMYCIN; TICAGRELOR; TICLOPIDINE; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; AGE; BARE METAL STENT; BLEEDING; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DRUG ELUTING STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS; MORTALITY; NONFATAL MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); MYOCARDIAL INFARCTION; PROCEDURES; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

EID: 84898684561     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/794078     Document Type: Review

References (37)

1. Levine G. N., Bates E. R., Blankenship J. C., 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology 2011 58 24 e44 e122 10.1016/j.jacc.2011.08.007
2. Wijns W., Kolh P., Danchin N., Guidelines on myocardial revascularization. European Heart Journal 2010 31 20 2501 2555 10.1093/eurheartj/ehq277
3. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G. M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., Colombo A., Incidence, predictors and outcome of thrombosis after succesful implantation of drug-eluting stents. The Journal of the American Medical Association 2005 293 17 2126 2130 2-s2.0-17844373254 10.1001/jama.293.17.2126
4. Eisenstein E. L., Anstrom K. J., Kong D. F., Shaw L. K., Tuttle R. H., Mark D. B., Kramer J. M., Harrington R. A., Matchar D. B., Kandzari D. E., Peterson E. D., Schulman K. A., Califf R. M., Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. The Journal of the American Medical Association 2007 297 2 159 168 2-s2.0-33846125284 10.1001/jama.297.2.joc60179
5. Park D.-W., Park S.-W., Park K.-H., Lee B.-K., Kim Y.-H., Lee C. W., Hong M.-K., Kim J.-J., Park S.-J., Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. The American Journal of Cardiology 2006 98 3 352 356 2-s2.0-33745966517 10.1016/j.amjcard.2006.02.039
6. Gwon H.-C., Hahn J.-Y., Park K. W., Song Y. B., Chae I.-H., Lim D.-S., Han K.-R., Choi J.-H., Choi S.-H., Kang H.-J., Koo B.-K., Ahn T., Yoon J.-H., Jeong M.-H., Hong T.-J., Chung W.-Y., Choi Y.-J., Hur S.-H., Kwon H.-M., Jeon D.-W., Kim B.-O., Park S.-H., Lee N.-H., Jeon H.-K., Jang Y., Kim H.-S., Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents. Circulation 2012 125 3 505 513 2-s2.0-84856452781 10.1161/CIRCULATIONAHA.111.059022
7. Kim B. K., Hong M. K., Shin D. H., A new strategy for discontinuation of dual antiplatelet therapy. Journal of the American College of Cardiology 2012 60 15 1340 1348 10.1016/j.jacc.2012.06.043
8. Park S. J., Park D. W., Kim Y. K., Duration of dual antiplatelet therapy after implantation of drug-eluting stents. The New England Journal of Medicine 2010 362 1374 1382 10.1056/NEJMoa1001266
9. Valgimigli M., Campo G., Monti M., Vranckx P., Percoco G., Tumscitz C., Castriota F., Colombo F., Tebaldi M., Fucà G., Kubbajeh M., Cangiano E., Minarelli M., Scalone A., Cavazza C., Frangione A., Borghesi M., Marchesini J., Parrinello G., Ferrari R., Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012 125 16 2015 2026 2-s2.0-84860135329 10.1161/CIRCULATIONAHA.111.071589
10. Hu T., Wang H. C., AS-171 Duration of dual antiplatelet therapy and outcomes after left main percutaneous coronary intervention. The American Journal of Cardiology 2012 109 7 S85 S86 10.1016/j.amjcard.2012.01.196
11. Cassese S., Byrne R. A., Tadad T., Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a metaanalysis of randomized trials. European Heart Journal 2012 33 24 3078 3087 10.1093/eurheartj/ehs318
12. http://hiru.mcmaster.ca/hiru/HIRU-Hedges-EMBASE-Strategies.aspx and http://hiru.mcmaster.ca/hiru/HIRU-Hedges-MEDLINE-Strategies.aspx
13. Higgins J. P., Altman D. G., Higgins J. P., Green S., Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 2008 Hoboken, NJ, USA Wiley-Blackwell 187 241
14. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G., Measuring inconsistency in meta-analyses. British Medical Journal 2003 327 7414 557 560 10.1136/bmj.327.7414.557 2-s2.0-0041876133
15. Moher D., Liberati A., Tetzlaff J., Altman D. G., The PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 6 7 e1000097 10.1371/journal.pmed.1000097
16. http://www.prisma-statement.org/
17. Pfisterer M., Brunner-La Rocca H. P., Buser P. T., Rickenbacher P., Hunziker P., Mueller C., Jeger R., Bader F., Osswald S., Kaiser C., Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. Journal of the American College of Cardiology 2006 48 12 2584 2591 2-s2.0-33845319222 10.1016/j.jacc.2006.10.026
18. Airoldi F., Colombo A., Morici N., Latib A., Cosgrave J., Buellesfeld L., Bonizzoni E., Carlino M., Gerckens U., Godino C., Melzi G., Michev I., Montorfano M., Sangiorgi G. M., Qasim A., Chieffo A., Briguori C., Grube E., Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007 116 7 745 754 2-s2.0-34547860049 10.1161/CIRCULATIONAHA.106.686048
19. Mehta S. R., Yusuf S., Peters R. J. G., Bertrand M. E., Lewis B. S., Natarajan M. K., Malmberg K., Rupprecht H.-J., Zhao F., Chrolavicius S., Copland I., Fox K. A. A., Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet 2001 358 9281 527 533 2-s2.0-0035908781 10.1016/S0140-6736(01)05701-4
20. Steinhubl S. R., Berger P. B., Tift Mann J. III, Fry E. T. A., DeLago A., Wilmer C., Topol E. J., Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. The Journal of the American Medical Association 2002 288 19 2411 2420 2-s2.0-0037145863 10.1001/jama.288.19.2411
21. Bernardi V., Szarfer J., Summay G., Mendiz O., Sarmiento R., Alemparte M. R., Gabay J., Berger P. B., Long-term versus short-term clopidogrel therapy in patients undergoing coronary stenting (from the randomized Argentine clopidogrel stent [RACS] trial). The American Journal of Cardiology 2007 99 3 349 352 2-s2.0-33846413580 10.1016/j.amjcard.2006.08.034
22. Grines C. L., Bonow R. O., Casey D. E. Jr., Gardner T. J., Lockhart P. B., Moliterno D. J., O'Gara P., Whitlow P., Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007 115 6 813 818 2-s2.0-33847149285 10.1161/CIRCULATIONAHA.106.180944
23. Kirtane A. J., Gupta A., Iyengar S., Moses J. W., Leon M. B., Applegate R., Brodie B., Hannan E., Harjai K., Jensen L. O., Park S.-J., Perry R., Racz M., Saia F., Tu J. V., Waksman R., Lansky A. J., Mehran R., Stone G. W., Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009 119 25 3198 3206 2-s2.0-67650755016 10.1161/CIRCULATIONAHA.108.826479
24. Räber L., Magro M., Stefanini G. G., Kalesan B., Van Domburg R. T., Onuma Y., Wenaweser P., Daemen J., Meier B., Jüni P., Serruys P. W., Windecker S., Very late coronary stent thrombosis of a newer-generation eerolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012 125 9 1110 1121 2-s2.0-84857913293 10.1161/CIRCULATIONAHA.111.058560
25. Stefanini G. G., Byrne R. A., Serruys P. W., Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. European Heart Journal 2012 33 10 1214 1222 10.1093/eurheartj/ehs086
26. Palmerini T., Biondi-Zoccai G., Riva D. D., Stettler C., Sangiorgi D., D'Ascenzo F., Kimura T., Briguori C., Sabat M., Kim H.-S., de Waha A., Kedhi E., Smits P. C., Kaiser C., Sardella G., Marullo A., Kirtane A. J., Leon M. B., Stone G. W., Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. The Lancet 2012 379 9824 1393 1402 2-s2.0-84859560982 10.1016/S0140-6736(12)60324-9
27. Zhang T., Shen L., Hu L., He B., Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis. The Journal of Clinical Pharmacology 2013 53 3 345 351 10.1177/0091270012448398
28. Ba B., Ma Y. T., Yu Z. X., Optimal duration of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis. Chinese Journal of Evidence-Based Medicine 2012 12 5 577 582
29. Valgimigli M., Park S.-J., Kim H.-S., Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: a meta-analysis of randomized trials. International Journal of Cardiology 2013 168 3 2579 2587 10.1016/j.ijcard.2013.03.047
30. Zhang T., Shen L., Hu L., Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis. The Journal of Clinical Pharmacology 2013 53 3 345 351 10.1177/0091270012448398
31. Valgimigli M., Borghesi M., Tebaldi M., Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging dual antiplatelet treatment after grading stent-induced intimal hyperplasia study (PRODIGY). European Heart Journal 2013 34 12 909 919 10.1093/eurheartj/ehs460
32. Yim J., Petrofsky J., Berk L., Differences in endothelial function between Korean-Asians and Caucasians. Medical Science Monitor 2012 18 6 CR337 CR343 10.12659/MSM.882902
33. Lee J. M., Park S., Shin D.-J., Choi D., Shim C. Y., Ko Y.-G., Kim J.-S., Shin E.-S., Chang C. W., Lee J.-E., Jang Y., Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. The American Journal of Cardiology 2009 104 1 46 51 2-s2.0-67649370752 10.1016/j.amjcard.2009.02.045
34. Byrne R. A., Schulz S., Mehilli J., Iijima R., Massberg S., Neumann F.-J., ten Berg J. M., Schömig A., Kastrati A., Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: the intracoronary stenting and antithrombotic regimen: safety and efficacy of 6 months dual antiplatelet therapy after drug-eluting stenting (ISAR-SAFE) study. American Heart Journal 2009 157 4 620.e2 624.e2 2-s2.0-63149181056 10.1016/j.ahj.2008.12.019
35. Mauri L., Kereiakes D. J., Normand S.-L., Wiviott S. D., Cohen D. J., Holmes D. R., Bangalore S., Cutlip D. E., Pencina M., Massaro J. M., Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal 2010 160 6 1035.e1 1041.e1 2-s2.0-78650097647 10.1016/j.ahj.2010.07.038
36. Feres F., Costa R. A., Abizaid A., Optimized duration of clopidogrel therapy following treatment with the endeavorzotarolimus-eluting stents in the real-world clinical practice (OPTIMIZE) trial: rationale, design and preliminary results of a large-scale, randomized, multicenter study. Journal of the American College of Cardiology 2011 57 14, supplement 1 E1729 10.1016/S0735-1097(11)61729-4
37. Helft G., Le Feuvre C., Georges J. L., Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial. Trials 2013 14, article 56 10.1186/1745-6215-14-56